Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study

INTRODUCTION: SURE Netherlands (NCT03929679) evaluated the use of once-weekly (OW) semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), in routine clinical care for individuals with type 2 diabetes (T2D). METHODS: Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolffenbuttel, Bruce H. R., Brugts, Michel P., Catarig, Andrei-Mircea, Clark, Alice, Kok, Maarten, Lieverse, Aloysius G., van Soest, Jaap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768392/
https://www.ncbi.nlm.nih.gov/pubmed/36542260
http://dx.doi.org/10.1007/s12325-022-02385-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768392/
https://www.ncbi.nlm.nih.gov/pubmed/36542260
http://dx.doi.org/10.1007/s12325-022-02385-x

Ejemplares similares